復宏漢霖(02696.HK)首個創新型單抗H藥漢斯狀獲批上市
復宏漢霖(02696.HK)宣佈,旗下首款自主研發的創新生物藥PD-1抑制劑H藥——漢斯狀(通用名:斯魯利單抗注射液)正式獲得國家藥品監督管理局(NMPA)批準,用於經既往標準治療失敗的、不可切除或轉移性微衛星高度不穩定(MSI-H)的成人晚期實體瘤適應症,爲患者提供治療新選擇,也爲國內腫瘤精準免疫治療賦能添勢,助力推進中國生物醫藥行業高質量發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.